Qps
1 known investors
QPS Holdings is a contract research organization providing preclinical and clinical drug development services to pharma and biotech.
Also known as QPS Holdings · QPS Holdings, LLC
Investors · 1
Company profile
researched Aug 2026QPS Holdings, LLC is a contract research organization (CRO) headquartered in Delaware, USA, serving pharmaceutical and biotechnology companies across the drug discovery and development spectrum. The company was founded in 1995 by Benjamin Chien, who continues to serve as Chief Executive Officer, and began as a small-molecule operation with three people in a single Delaware office.
QPS's service portfolio spans pharmacology, DMPK, toxicology, bioanalysis and translational medicine, together with biological materials and cell-based offerings such as leukopaks, PBMCs and cell therapy products. Client programs supported by the company include work in obesity, type 2 diabetes, oncology, CNS diseases, and cell and gene therapy. The organization operates laboratories and facilities equipped for instrument-based analytical and bioanalytical workflows used in discovery and clinical-stage studies.
In April 2024, QPS divested its Neuropharmacology business unit, a preclinical CNS-focused drug discovery operation founded in 1999 and based in a 2,700 m² facility in Grambach, Austria with more than 80 employees, to the Danish preclinical CRO Scantox and its majority owner Impilo; the unit was renamed Scantox Neuro GmbH.
Founding story
QPS was founded in 1995 by Benjamin Chien and started as a small-molecule shop of three people operating from a single office in Delaware.
Business model
QPS operates as a contract research organization, conducting outsourced discovery, preclinical and clinical research studies on behalf of pharmaceutical and biotechnology clients.
Latest developments
QPS celebrated its 30th anniversary in 2025. In April 2024 it closed the divestment of its Neuropharmacology business unit to Scantox Group, which rebranded the Austrian operation as Scantox Neuro GmbH.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned as a global, full-service CRO serving pharmaceutical and biotechnology clients across the drug development spectrum, with an emphasis on data quality, technical expertise and adherence to study timelines.
Technology
The company maintains instruments, platforms and processes for bioanalysis and drug development studies, including pharmacology, DMPK, toxicology and translational medicine capabilities, and supplies biological materials such as leukopaks, PBMCs and cell therapy products.
Go-to-market
Pharmaceutical and biotechnology companies running drug discovery and development programs, including in obesity, type 2 diabetes, oncology, CNS disorders, and cell and gene therapy.
Geography
Headquartered in Delaware, USA, with eight locations across the United States, Europe, Asia and Australia. Its former Neuropharmacology unit was located in Grambach, Austria.
History
From a single Delaware office established in 1995, QPS expanded into a global, full-service CRO with eight locations across the United States, Europe, Asia and Australia and approximately 1,200 staff. Over three decades it broadened its offering from small-molecule work to pharmacology, DMPK, toxicology, bioanalysis, translational medicine and cell therapy-related services. In April 2024 the company completed the divestment of its Austria-based Neuropharmacology business unit to Scantox, which had announced the intended acquisition in November 2023. QPS marked its 30th anniversary in 2025.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsQPS Holdings, LLC celebrated its 30th anniversary in 2025, having grown from a three-person small-molecule shop in a single Delaware office to a global CRO with eight locations and 1,200 staff.
Scantox, together with its majority owner Impilo, closed the acquisition of QPS Neuropharmacology, a preclinical CNS drug discovery CRO founded in 1999 with a 2,700 m² facility in Grambach, Austria and more than 80 employees. The unit was integrated into Scantox Group as Scantox Neuro GmbH. The intended acquisition had been announced in November 2023.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Quincy Public Schools Foundation awards $80K in grantswgem.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Qps do?
- QPS Holdings is a contract research organization providing preclinical and clinical drug development services to pharma and biotech.
- Who are Qps's investors?
- Qps's investors include The Argentum Group.